Prostate Cancer - Oct 18, 2018 Edition

Medical News | Medical Articles

Prostate Cancer - Oct 18, 2018 Edition

October 18, 2018     Prostate Cancer     The latest prostate cancer news from News Medical

Men who consume alcohol during adolescence are more likely to have prostate cancer   Compared with non-drinkers, men who consumed at least seven drinks per week during adolescence had three times the odds of being diagnosed with clinically significant prostate cancer.

Research team identifies new therapeutic target for castration-resistant prostate cancer   A collaborative research team has linked the development of castration-resistant prostate cancer and resistance to treatment to a lack of androgen receptor expression in prostate cancer cells, identifying a new therapeutic target for one of the deadliest forms of cancer among men.         Prostatectomy plus radiotherapy associated with greater survival in prostate cancer patients   High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective than the other.

US Department of Defense offers three-year grant for UIC study on prostate cancer   A new three-year grant totaling nearly $1 million from the U.S. Department of Defense will fund University of Illinois at Chicago research on the gene SELENOF and its role in the development of prostate cancer among black men.       New genetic marker could improve diagnosis of prostate cancer   Scientists have discovered a link between certain genetic mutations, the aggressiveness of prostate cancer, risk of developing the disease and poorer survival rates of patients.       New guideline supports hypofractionated radiation therapy for men with prostate cancer   Three prominent medical societies today issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external beam radiation therapy (EBRT). Adoption of the guideline could make treatment shorter and more convenient for many patients with prostate cancer, the most common malignancy among American men.       Crown Bioscience announces successful validation of well-characterized prostate cancer PDX models   Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft models of prostate cancer.

Website: www.news-medical.net Email: info@news-medical.net Telephone: +44 (0)161 457 7150 AZoNetwork UK Ltd. NEO, 4th Floor 9 Charlotte Street, Manchester M1 4ET, UK